Monitor for actual Form 4 filings to confirm execution of these sales. The trust restructuring and conversion of LP interests suggest a planned liquidity event rather than opportunistic selling. Given the former-affiliate status and the shares' origin from legacy LP interests, this is not a red flag for current management's confidence. No immediate trading action warranted.
Price Chart
Executive Summary
Errol B. De Souza, a former affiliate of Royalty Pharma, filed two Form 144 notices on August 12, 2026, signaling intent to sell a combined 331,352 Class A ordinary shares. The first filing covers 206,352 shares (approx. $11.9M at the filing date) from the Errol Bento De Souza Revocable Trust, and the second covers 125,000 shares (approx. $7.2M) from the De Souza 2021 Irrevocable Trust. Both blocks were acquired via conversion of LP interests on August 7, 2026, and are being sold through J.P. Morgan. While the total ~$19.1M sale is notable, De Souza is a former affiliate (not current management), and the shares originate from a trust restructuring, not an open-market accumulation, reducing the signal of negative insider sentiment. The filing is routine in nature for a former affiliate monetizing legacy holdings, but the size warrants attention given the company's $33.2B market cap and the historical calibration showing high win rates on prior RPRX reports (89% T+20). Impact is neutral-to-low — this is a planned liquidity event, not a distress signal.
Key Facts
- Errol B. De Souza, a former affiliate, filed two Form 144 notices to sell a total of 331,352 Class A ordinary shares of Royalty Pharma.
- First filing: 206,352 shares (~$11.9M) from the Errol Bento De Souza Revocable Trust.
- Second filing: 125,000 shares (~$7.2M) from the De Souza 2021 Irrevocable Trust.
- Both share blocks were acquired on August 7, 2026, via conversion of LP interests originally received from the issuer on June 16, 2020.
- Sales are to be executed through J.P. Morgan Securities LLC as agent.
- De Souza is a former affiliate, not current management, reducing the insider-signal weight.
Financial Impact
Combined proposed sale of 331,352 shares valued at approximately $19.1 million based on filing-date prices ($11.9M + $7.2M).
Risk Factors
- If additional former affiliates or current management file similar large 144s in the coming weeks, it could signal broader insider distribution.
- Execution of the full 331,352 shares over a short period could create modest selling pressure, though the $19.1M total is small relative to RPRX's $33.2B market cap (0.06%).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (RPRX) — Batch item 1 | 0001968582-26-000828 |
| Document: 0001968582-26-000828-index.html | 0001968582-26-000827 |
| Document: 0001968582-26-000828.txt | 0001968582-26-000828 |
| 144 Filing (RPRX) — Batch item 4 | 0001968582-26-000827 |
| Document: 0001968582-26-000827-index.html | 0001968582-26-000828 |
| Document: 0001968582-26-000827.txt | 0001968582-26-000828 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | Press Release | $60.59 $58.47 | ▲ +3.50% | ▲ +2.38% | $57.16 (+5.66%) |
Aug 19, 2026 6w ago | Insider Cluster | $61.73 $61.80 | ▲ +0.11% | ▲ +0.50% | $57.16 (−7.40%) |
Aug 12, 2026 7w ago | 144 | $58.56 $60.58 | ▲ +3.45% | ▲ +5.41% | $57.16 (−2.39%) |
Aug 5, 2026 8w ago | 8-K | $57.75 $59.22 | ▲ +2.55% | ▲ +2.19% | $57.16 (−1.02%) |
Jul 2, 2026 13w ago | Insider Cluster | $57.77 $57.96 | ▲ +0.33% | ▼ −0.60% | $57.16 (−1.06%) |
Jul 2, 2026 13w ago | Insider Cluster | $57.77 $57.96 | ▲ +0.33% | ▼ −0.60% | $57.16 (−1.06%) |
May 28, 2026 18w ago | Insider Cluster | $55.76 $55.87 | ▲ +0.20% | ▲ +2.72% | $57.16 (+2.51%) |
May 28, 2026 18w ago | 8-K | $55.76 $54.97 | ▼ −1.42% | ▼ −1.12% | $57.16 (+2.51%) |
May 22, 2026 19w ago | Insider Cluster | $54.50 $55.18 | ▲ +1.25% | ▼ −0.41% | $57.16 (+4.88%) |
May 15, 2026 19w ago | Insider Cluster | $52.07 $53.86 | ▲ +3.44% | ▲ +1.82% | $57.16 (+9.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access